Microvast Powers the Next Generation of Electric Commercial Vehicles with Groundbreaking Battery Technology at IAA Transportation 2024
16.9.2024 19:11:00 CEST | Business Wire | Press release
Microvast Holdings, Inc. (NASDAQ: MVST) (“Microvast”, the “Company”, “we” or “our”), a technology innovator that designs, develops, and manufactures lithium-ion battery solutions, is advancing the adoption of electric commercial vehicles by launching its latest high-performance battery solutions at IAA Transportation 2024. The new lineup includes the introduction of silicon-based HnSO Cells, Lithium Titanate Oxide (LTO) Cells, and the third-generation MV-I Pack, offering an unprecedented combination of energy density, safety, and sustainability.
Microvast’s advanced battery solutions are designed to meet the rigorous energy demands of commercial transportation, enabling manufacturers to accelerate their shift to cleaner, more efficient electric powertrains.
Technological highlights and new products at IAA Transportation 2024:
- HnSO Cells (introduction of silicon-based cell technology): With an energy density of 300 Wh/kg, these cells provide high energy density, long cycle life (exceeding 4,000 cycles), and reduced total cost of ownership (TCO), making them ideal for long-range BEV and HEV applications.
- Lithium Titanate Oxide (LTO) Cells: Known for their enhanced safety and long cycle life of up to 20,000 cycles, LTO cells offer an energy density of 100Wh/kg, optimized for ultra high-power applications in challenging environments.
- Third Generation MV-I Pack: A robust, lightweight, turn-key solution featuring up to 200 Wh/kg energy density and over 5,000 full cycles. The MV-I Pack also integrates Microvast's 5th generation Battery Management System (BMS), ensuring compliance with ISO 26262 ASIL-C and advanced cybersecurity standards.
Additionally, Microvast introduces our fifth generation Battery Management System (BMS 5.0). BMS 5.0 is engineered for maximum functional safety, adhering to ISO 26262 ASIL-C standards and ISO/SAE 21434:2021 cybersecurity standards. This system ensures the highest levels of safety and security for electric vehicle operations.
Microvast’s latest comprehensive solutions for electric commercial vehicles contain an array of cell, module, and pack solutions, providing a one-stop solution for electric commercial vehicle applications with various operational profiles. With vertical integration from raw materials to turn-key solutions, Microvast offers scalable and versatile products tailored to meet the specific needs of different commercial operations.
“Our new battery technology marks a significant advancement for electric commercial vehicles, boasting increased energy density. The rapid charging capabilities facilitate enhanced mobility, while the cycle life is reliably extended. We’re driving the future of electric mobility with solutions that improve efficiency and reduce emissions,” said Dr. Wenjuan Mattis, CTO of Microvast.
Faster innovation, tailored customization, and exceptional quality: the future of e-mobility
Microvast’s vertically integrated model allows for complete control over all phases of development, from R&D to manufacturing. This unique model allows for faster innovation, tailored customization, and exceptional quality, providing commercial vehicle manufacturers with complete, scalable solutions that meet their specific operational needs.
Stefan Herr, Executive Vice President Microvast EMEA, added, “Our innovative battery technology is just the beginning. With a full-service approach, we provide end-to-end solutions for our customers — from tailored energy systems to ongoing support and optimization. We’re committed to delivering not just advanced technology, but a seamless, reliable partnership that ensures maximum performance and long-term success for electric commercial vehicle manufacturers and fleet operators alike.”
Reduced carbon emissions as a commitment to sustainability
Microvast’s mission is rooted in sustainability. The company is dedicated to advancing battery technology to accelerate the adoption of electric vehicles, reduce carbon emissions, and contribute to a greener planet. With over 17 years of manufacturing expertise, more than 30,000 installed battery systems worldwide, and a global presence in over 34 countries, Microvast acts as a trusted partner in the global transition to sustainable transportation.
About Microvast
Microvast is a global leader in providing battery technologies for electric vehicles and energy storage solutions. With a legacy of over 17 years, Microvast has consistently delivered cutting-edge battery systems that empower a cleaner and more sustainable future. The Company's innovative approach and dedication to excellence have positioned it as a trusted partner for customers around the world. Microvast was founded in 2006 and is headquartered in Stafford, Texas.
For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results; our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook,” or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding Microvast’s industry and market sizes, future opportunities for Microvast, and Microvast’s estimated future results. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic, and competitive uncertainties, and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915144080/en/
Contacts
Investor Relations Contact
Investor Relations Contact
ir@microvast.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom